Skip to main content
. 2018 Jul;10(7):4127–4136. doi: 10.21037/jtd.2018.06.04

Table 1. Patients’ characteristics, treatments, pathology findings, and outcome according to the kind of surgery.

Variables All Thymomectomy Radical thymectomy P
No. of patients 157 (100%) 86 (54.8%) 71 (45.2%)
Age 57±14 58±14 56±14 0.202
Gender (males), n (%) 76 (48.4) 41 (47.7) 35 (49.3) 0.873
MG, n (%) 22 (14.0) 0 22 (31.0) <0.001
Charlson index 1.78±1.60 2.00±1.67 1.49±1.47 0.073
WHO predominant histology, n (%) 0.055
   A 21 (13.4) 10 (11.6) 11 (15.5)
   AB 45 (28.7) 32 (37.2) 13 (18.3)
   B1 27 (17.2) 12 (14.0) 15 (21.1)
   B2 22 (14.0) 12 (14.0) 10 (14.1)
   B3 27 (17.2) 10 (11.6) 17 (23.9)
   Carcinoma 15 (9.6) 10 (11.6) 5 (7.0)
Masaoka stage, n (%) 0.724
   I 41 (26.1) 20 (23.3) 21 (29.6)
   II 74 (47.1) 44 (51.2) 30 (42.3)
   III 29 (18.5) 15 (17.4) 14 (19.7)
   IV 13 (8.3) 7 (8.1) 6 (8.5)
Incomplete resection, n (%) 16 (10.2) 9 (10.5) 7 (9.9) 1.000
   R1 resection 10 (6.4) 6 (7.0) 4 (5.6)
   R2 resection 6 (3.8) 3 (3.5) 3 (4.2)
Approach, n (%) 0.944
   Open 123 (78.3) 68 (79.1) 55 (77.5)
   VATS 29 (18.5) 15 (17.4) 14 (19.7)
   Conversion 5 (3.2) 3 (3.5) 2 (2.8)
Extended surgery, n (%) 55 (35.0) 27 (31.4) 28 (39.4) 0.317
Complications, n (%) 33 (21.0) 15 (17.4) 18 (25.4) 0.243
Post-operative stay 5 [0–30] 5 [2–28] 5 [0–30] 0.227
Multimodality therapy, n (%) 50 (31.8)
   Neoadjuvant chemo 17 (10.8) 10 (11.6) 7 (9.9) 0.800
   Neoadjuvant RT 3 (1.9) 2 (2.3) 1 (1.4) 1.000
   Adjuvant chemo 11 (7.0) 6 (7.0) 5 (7.0) 1.000
   Adjuvant RT (PORT) 36 (22.9) 20 (23.3) 16 (22.5) 1.000

WHO, World Health Organization; VATS, video-assisted thoracic surgery; RT, radiotherapy; PORT, post-operative radiotherapy.